Autoantibodies against pancreas

CIBD Profile

Transfected cells: autoantibodies against CUZD1 and GP2 (top); EOH-fixed and LFS-granulocytes (middle); intestinal goblet cells and S. cerevisiae (bottom)
  • Screening and differentiation test for the detection of antibodies in chronic inflammatory bowel diseases (CIBD): pancreas antigens rPAg1 and rPAg2, intestinal goblet cells, granulocytes (EOH), lactoferrin-specific (LFS) granulocytes, Saccharomyces cerevisiae.
  • Indication: Crohn's disease, ulcerative colitis.
  • Initial dilution: pancreas antigens, intestinal goblet cells and granulocytes 1:10 (IgA, IgG), S. cerevisiae 1:100 (IgA), 1:1000 (IgG).
  • For serological diagnosis of ulcerative colitis the indirect immunofluorescence test uses goblet cells (differentiated intestinal cells) for the detection of autoantibodies against intestinal goblet cells, and ethanol-fixed (EOH-fixed) granulocytes for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). Another important antibody associated with ulcerative colitis is directed against DNA-bound lactoferrin. For the determination of these autoantibodies granulocytes selectively reacting with lactoferrin (LFS granulocytes) are used.
  • The investigation of antibodies against exocrine pancreas (rPAg 1 + 2) and antibodies against S. cerevisiae is used for serological diagnosis of Crohn‘s disease. For the detection of antibodies against pancreas antigens rPAg1 (CUZD1) and rPAg2 (GP2) transfected cells are used as the standard substrate. 
  • Differential diagnosis is most efficient using a substrate combination of goblet cells, granulocytes, rPAg1 / rPAg2 and S. cerevisiae. If LFS granulocytes are used in addition (e.g. FA 1391-4), the hit rate for the serological diagnosis of chronic inflammatory bowel diseases can be increased significantly.

ProductOrder number
CIBD Profile 3FA 1391-4
Lactoferrin-specific granulocyte BIOCHIPsFA 1215-1